Predictive value of alkaline phosphatase for response and time to progression in bortezomib‐treated multiple myeloma patients

Myeloma bone disease is characterized by osteolytic destruction associated with suppressed osteoblastic activity. Using data from the APEX (Richardson et al., N Engl J Med 2005;352:2487–2498) study, we have assessed the relationship of changes in alkaline phosphatase (ALP) levels during bortezomib therapy with response and time to progression on this therapy. The percentage of ALP increments in responders (complete and partial response) and nonresponders was analyzed at different thresholds and time points. For all bortezomib‐treated patients enrolled in the trial (N = 333), at least a 25% increase in ALP from the baseline at 6 week was the most powerful predictor of treatment response (P < 0.0001) and time to progression (206 vs. 169 days) relative to patients with less than a 25% increase in ALP (P = 0.01). Markers of osteoblastic activation may predict quality and duration of response in multiple myeloma. In addition, our data suggest that bone anabolism could inhibit myeloma growth. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.

[1]  B. Barlogie,et al.  Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. , 2006, Haematologica.

[2]  O. Sezer,et al.  Treatment of Bortezomib Increases Osteoblast Function in Patients with Multiple Myeloma. , 2005 .

[3]  Meredith O'Keeffe,et al.  Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. , 2005, Blood.

[4]  D. Esseltine,et al.  Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. , 2005, Blood.

[5]  D. Esseltine,et al.  Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma , 2005, British journal of haematology.

[6]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[7]  M. Dimopoulos,et al.  Role of receptor activator of nuclear factor‐kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1‐alpha (MIP‐1a) in monoclonal gammopathy of undetermined significance (MGUS) , 2004, British journal of haematology.

[8]  G. Roodman.  Mechanisms of bone metastasis. , 2004, Discovery medicine.

[9]  R. Bataille,et al.  New Insights in Myeloma-induced Osteolysis , 2003, Leukemia & lymphoma.

[10]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[11]  J. Kanis,et al.  Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption , 1992, European journal of haematology.

[12]  R. Bataille,et al.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. , 1991, The Journal of clinical investigation.